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Introduction
Crohn's disease (CD) and ulcerative colitis (UC) represent the two main types of inflammatory bowel disease (IBD) [1, 2] . There is increasing evidence that IBD results from an inappropriate inflammatory response to intestinal microbes in a genetically susceptible host [1, 2] . The majority of IBD patients will suffer from a chronic disease course with the development of tissue damage related to the long-standing inflammatory activity [3] . As such, the vast majority of IBD patients will need long-term anti-inflammatory treatments, not only for short-term symptom control but also to reduce the risk of subsequent bowel damage [4, 5] .
Inevitably, IBD drugs may also be associated with drugrelated side effects [6] . Examples include dermatological complications such as the development of a paradoxical psoriasiform skin reaction under tumor necrosis factor (TNF)-antagonist therapy or an increased risk of nonmelanomatous skin cancer under thiopurines [7] . The frequency and type of side effects of drugs used for IBD treatment are typically reported in the medical literature on the basis of the use of single drugs [8] . However, in daily practice, IBD drugs are frequently combined. Examples include the use of combined therapy with azathioprine and infliximab that has been associated with better clinical and endoscopic remission rates in CD patients naive to treatment when combined with the single use of either infliximab and azathioprine and the combined use of these substances in CD patients to reduce the risk for anti-TNF-antagonist antibody formation [9, 10] .
However, the multiplicity of treatments may increase the likelihood of development of side effects. For instance, although monotherapy with adalimumab was not associated with an increase in malignancies, combination therapy with azathioprine clearly was [11] .
Given the fact that there is a paucity of cohort studies providing a global view of the type and frequency of drugrelated adverse events, we initiated this investigation to address the following questions: first, what is the frequency and type of adverse events related to single drug treatments in IBD patients? Second, what is the frequency of adverse events related to the use of multiple (at least two) drug treatments in IBD patients? Third, do particular risk factors besides the use of the drug itself exist that can be linked to the occurrence of drug-related side effects?
Patients and methods

Patients
The Swiss Inflammatory Bowel Disease Cohort (SIBDC) has been including IBD patients from all regions of Switzerland since 2006. The SIBDC is supported by the Swiss National Science Foundation and is approved by local ethics committees [12] . For inclusion, patients have to be at least 18 years old and need to provide written informed consent. In addition, a permanent residence status in Switzerland and/or Swiss health insurance coverage is mandatory. Patients can be included in the cohort if a diagnosis of CD, UC, or IBD unclassified has been established at least 4 months before inclusion, or if they had at least one episode of symptom recurrence [12] . Patients are prospectively included if the diagnosis of IBD has been established in 2006 or later; a retrospective inclusion of patients diagnosed with IBD in 2005 and earlier is also possible. At the time of inclusion, patients undergo a thorough clinical and laboratory assessment. Clinical, socioeconomic, and psychosocial data are collected. The treating physicians complete physician-reported outcomes, whereas the patients complete patient-reported outcomes such as questionnaires on quality of life. Disease location is recorded according to the Montréal classification [13] . After enrollment, patients and physicians complete a yearly follow-up questionnaire. Patients included in this study were recruited in the following settings of care: 61% in university hospitals, 13% in large nonuniversity hospitals, 6% in regional hospitals, and 20% in private practices.
Methods
The collected data were entered into a Microsoft Access database (Access 2000; Microsoft Switzerland Ltd Liab. Co., Wallisellen, Switzerland) at the datacenter of the SIBDC, which is located at the Institute of Social and Preventive Medicine, University of Lausanne. For the purpose of this manuscript, the analysis was based on the validated data obtained from IBD patients enrolled into the SIBDC between May 2006 and April 2016 (10 years period). Data were extracted from physician questionnaires that record on-treatment adverse events that required drug cessation during the entire disease history. The following drug categories were analyzed: aminosalicylates [5-aminosalicylic acid (5-ASA)], steroids [topical (budesonide capsules or enema) and systemic steroids were analyzed separately], thiopurines, methotrexate, TNF-antagonists, and calcineurin inhibitors (tacrolimus, cyclosporine). The follow-up questionnaires of the cohort do not assess the time interval (months) at which the particular drug was administered, and they also did not capture any follow-up information after a particular adverse event had developed that led to drug cessation.
Statistical analysis
Data were retrieved from the database of the SIBDC at the Institute of Social and Preventive Medicine of University of Lausanne. All statistical analyses were carried out by the cohort statistician (N.F.) using the statistical package program Stata (version 12.1; StataCorp., College Station, Texas, USA). Quantitative data distribution was analyzed using normal-QQ-plots. Results of quantitative data are presented either as median plus interquartile ranges (for data with a non-Gaussian distribution) or as mean SD and range (for normally distributed data). Categorical data were summarized as the percentage of the group total. For quantitative data, differences in distribution between two groups were evaluated using either the Wilcoxon-Mann-Whitney rank test (for data with a nonGaussian distribution) or the Student t-test (for normally distributed data). For categorical outcomes, differences in the observed frequencies between groups were compared using the χ 2 -test or the exact Fisher's test for groups with a small number of observations (n < 20). A Bonferroni adjustment was used throughout in case of multiple testing. A P-value of less than 0.05 was considered statistically significant. Stepwise multiple logistic regression modeling was performed to evaluate the association between potential risk factors and the appearance of drug-related adverse events leading to drug cessation. The variables tested as potential risk factors were sex, age at the time of IBD diagnosis, disease duration, IBD family history, presence of extraintestinal manifestations (EIM), smoking status, BMI, IBD-related surgery, and the number of concomitantly used IBD drugs. In a first step, the potential risk factors were each tested separately. In a second step, all risk factors with a P-value less than 0.2 were entered together into the multivariate logistic regression model.
Results
Baseline characteristics
A total of 3192 patients were included, of whom 1792 (56.1%) had CD, 1322 (41.4%) had UC, and 78 (2.5%) had IBD unclassified. Of 3138 patients treated with IBD drugs, 2129 (67.8%) presented with one or several drug-related side effects that required drug cessation (Table 1 ). Disease duration of IBD patients with and without treatment adverse events was similar (median 12 years for both groups, P = 0.675). The age at enrollment into the SIBDC was again similar between the groups with and without therapy adverse events that necessitated a drug cessation. No relevant differences were noted with respect to disease location for CD and UC between the groups with and without treatment adverse events. It is noteworthy that IBD patients who experienced drug-related side effects underwent combined treatments with two and more IBD drugs significantly more frequently compared with IBD patients without drug-related side effects (P < 0.001).
IBD drug cessation in the SIBDC Godat et al.
www.eurojgh.com
Frequencies and types of inflammatory bowel disease drug-related adverse events
In Table 2 , we present the IBD drug-related adverse events during the entire disease course stratified according to IBD Data are presented as n (%). Disease location is indicated according to the Montréal classification [13] . CD, Crohn's disease; IBD, inflammatory bowel disease; IBDU, inflammatory bowel disease of undetermined origin; IQR, interquartile range; UC, ulcerative colitis.
a
The P-value refers to the comparison between IBD patients with versus without adverse drug event.
type. The lowest frequency of IBD drug adverse events necessitating drug cessation was observed for topical and systemic steroids (5.3 and 4.7%), followed by aminosalicylates (7.9%). The frequency of drug-related side effects necessitating treatment discontinuation for azathioprine, mercaptopurine, and methotrexate was 25.1, 30.1, and 19.8%, respectively. Figure 1 shows the frequency of drugrelated side effects necessitating drug cessation in IBD patients during their entire disease history, stratified according to IBD diagnosis. A detailed overview of the distinct types of IBD drugrelated adverse events, stratified according to distinct drug classes and IBD diagnosis, is available in Supplementary Table 1 (Supplemental digital content 1, http://links.lww.com/ EJGH/A258). Use of 5-ASA was generally associated with a low prevalence of adverse drug reactions that necessitated drug cessation. Nephritis requiring 5-ASA cessation was observed in 0.3% of patients. Steroids had to be stopped in 0.2% of treated patients because of osteopenia/osteoporosis, in 0.2% of treated patients because of psychological intolerance, and in 0.1% of steroid-treated patients because of diabetes. Mercaptopurine had to be discontinued because of leukopenia, hepatotoxicity, and pancreatitis in 2.7, 2.3, and 1.1% of treated patients, respectively. Azathioprine had to be stopped because of leukopenia, hepatotoxicity, and pancreatitis in 1.2, 0.8, and 1.2%, respectively. No lymphoma was reported in patients being treated with thiopurines. In 0.3% of patients treated with methotrexate, a discontinuation of therapy because of liver fibrosis/cirrhosis was reported. Gastrointestinal intolerance necessitated methotrexate cessation in 4.8% of treated patients.
Cyclosporine had to be stopped in 3.8% of treated patients because of renal hypertension. Hypersensitivity reactions necessitating drug cessation were documented in 2.5% of patients under infliximab compared with 1.0% of patients under adalimumab and 1.8% of patients under certolizumab. We identified one patient with pulmonary tuberculosis who required infliximab cessation. There was no tuberculosis case requiring cessation of treatment with adalimumab and certolizumab, respectively. The overall rate of infections necessitating the cessation of TNF-antagonists was very low [0%, 95% confidence interval (CI): 0-1.7%]. Injection-site reactions required adalimumab discontinuation in 0.2% of treated patients. The three different TNF-antagonists had a similar distribution in the frequency of other adverse events such as asthenia, fever, headache, arthralgia, nausea, or abdominal pain requiring drug cessation.
Frequency and type of inflammatory bowel disease drugrelated adverse events in patients under combined regimens
We analyzed the prevalence of drug-related side effects necessitating drug discontinuation in relation to the number of IBD drugs used. The majority of drug-related side effects that required drug cessation developed in IBD patients under monotherapy with an IBD drug ( Table 3) .
The number of concomitantly used IBD drugs increased the risk for the development of IBD drug-related adverse events that required IBD drug cessation (Table 4) . When looking at all IBD patients together, patients under IBD drug monotherapy had a cumulative frequency of 10.3% of drug-related side effects that necessitated drug cessation. This risk increased to 19.0% in IBD patients being treated with two IBD drugs and 26.0% in IBD patients being treated with at least three IBD drugs (Table 4) . CD patients more frequently developed IBD drug-related side effects that necessitated drug cessation compared with UC patients (12.5 vs. 6.8% for patients under monotherapy, P = 0.001; 21.3 vs. 15.2% for patients under combined therapy with two drugs, P = 0.010; and 33.3 vs. 21.1% for patient treated with at least three IBD drugs, P = 0.002). Figure 2 shows the frequency of drug-related adverse events requiring IBD drug cessation in relation to the number of concomitantly used IBD drugs.
Systematic analysis of risk factors for inflammatory bowel disease drug-related adverse events necessitating treatment discontinuation
We systematically analyzed the risk for the occurrence of IBD drug-related side effects necessitating cessation of com treatment by the means of logistic regression modeling. We first analyzed the risk factors for IBD drug-related side effects in the entire IBD population (Table 5 ). In the univariate logistic regression model, we found that female sex, CD diagnosis, the presence of EIM, IBD-related surgery, and the number of concomitantly used IBD drugs were associated significantly with an increased risk for the occurrence of IBD drug-related side effects necessitating discontinuation of drug. There was also a trend for disease duration more than 10 years to be associated with the risk of drug-related adverse events requiring discontinuation of drug. All factors from the univariate analysis with a P-value less than 0.2 were entered into the multivariate model. In the multivariate model, we identified CD diagnosis [odds ratio (OR) = 1.361], presence of EIM (OR = 2.262), IBD-related surgery (OR = 1.419), and the increasing number of concomitantly used IBD drugs (OR = 2.007 for two concomitantly used IBD drugs; OR = 3.225 for at least three concomitantly used IBD drugs) to be associated significantly with the occurrence of IBD drug-related adverse events that necessitated drug cessation. The use of at least three concomitantly used IBD drugs showed the strongest association with IBD drugrelated adverse events necessitating drug cessation among all the analyzed risk factors. The analyses for CD and UC patients are shown in Supplementary Tables 2 and 3 (Supplemental digital content 1, http://links.lww.com/EJGH/A258). In CD patients, the multivariate model identified the presence of EIM (OR = 2.556), IBD-related surgery (OR = 1.367), and the number of concomitantly used IBD drugs (OR = 1.906 for two concomitantly used IBD drugs; OR = 3.589 for at least three concomitantly used IBD drugs) to be associated significantly with IBD drug-related side effects requiring drug cessation. Again, the use of at least three concomitantly used IBD drugs showed the strongest association with IBD drug-related adverse events necessitating drug cessation among all the analyzed risk factors (Supplementary In UC patients, the multivariate model identified the presence of EIM (OR = 1.937), IBD-related surgery (OR = 1.506), and the number of concomitantly used IBD drugs (OR = 2.229 for two concomitantly used IBD drugs; OR = 2.991 for at least three concomitantly used IBD drugs) to be associated significantly with IBD drugrelated side effects requiring drug cessation. Smoking was identified as a protective factor (OR = 0.525) for IBD drug-related side effects.
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Discussion
We present data of a large national cohort study evaluating the frequency and type of IBD drug-related side effects that necessitated treatment discontinuation. Our study yielded several results that are clinically relevant. First, over a median disease duration of 12 years, the majority (67.8%) of patients experienced IBD drug-related side effects that required treatment discontinuation. Second, drug-related side effects requiring treatment discontinuation were most frequently observed for thiopurines, followed by methotrexate, TNF-antagonists, cyclosporine, 5-ASA, and steroids. Third, the number of concomitantly used IBD drugs was the strongest predictor for experiencing IBD drug-related side effects necessitating treatment discontinuation.
We first discuss drug-related side effects necessitating treatment cessation according to the observed frequencies of the different drugs. Azathioprine and mercaptopurine are steroid-sparing drugs that have been used to treat CD and UC for over 50 years [14] . We found a frequency of drug-related side effects requiring treatment cessation in 25.1% of IBD patients treated with azathioprine and in 30.1% of patients treated with 6-mercaptopurine (6-MP). Leukopenia, pancreatitis, and gastrointestinal intolerance were the dominant reasons for thiopurine cessation. Our data are in agreement with the study by Chaparro et al. [15] , who evaluated the incidence of thiopurine-related adverse events in 3931 patients with a median follow-up of 44 months (range: 0-420 months). They observed a cumulative incidence of adverse events of 26%, with an annual risk of 7% for patient-year of treatment. The most frequent adverse events were nausea (8%), hepatotoxicity (4%), myelotoxicity (4%), and pancreatitis (4%). A total of 17% of patients had to discontinue thiopurines because of these adverse events [15] . The higher frequency of adverse events leading to thiopurine cessation in the SIBDC can be explained by the longer follow-up in our cohort. The fact that we observed 6-MP-related side effects leading to drug cessation in 30.1% of treated patients represents a selection bias as 6-MP is mostly used in patients who have already experienced an adverse drug event under azathioprine.
We observed methotrexate-related adverse events leading to drug cessation in 19.8% of treated patients. Gastrointestinal intolerance (nausea, vomiting, elevated liver enzymes) was the dominant reason (27%) to discontinue methotrexate. Our findings are in agreement with the literature reporting that the typical side effects of methotrexate therapy include liver toxicity, dyspnea, IBD drug cessation in the SIBDC Godat et al. www.eurojgh.comnausea, vomiting, fatigue, and neutropenia [16] . Goodman et al. [17] found that 30% of patients treated with methotrexate for at least 5 years discontinued therapy because of adverse effects. Other studies reported a side effect rate as low as 17%, with withdrawal of methotrexate in only 8% of patients [18] . The rate of discontinuation for methotrexate observed in our cohort is also between these values. It is noteworthy that higher prevalence rates for methotrexaterelated adverse events were observed (74 vs. 38%) in patients who did not receive folic acid supplementation [18] . The questionnaires of the SIBDC did not systematically assess concomitant supplementation with folic acid. Monoclonal antibodies directed against TNF-α are used to treat IBD patients with moderate-to-severe clinical activity not responding to conventional medical therapy. Infliximab, adalimumab, and certolizumab pegol are approved for the induction and maintenance of remission in CD [19] [20] [21] , whereas infliximab, adalimumab, and golimumab are approved for the induction and maintenance of remission in UC [22] [23] [24] . Well-known adverse events of anti-TNF therapy are an increased risk of serious and opportunistic infections, infusion reactions (for infliximab), skin reactions (for adalimumab and certolizumab pegol), autoimmunity, heart failure, and risk of melanoma. In our cohort, we observed a discontinuation rate because of side effects of infliximab in 20.6%, certolizumab pegol in 15%, and adalimumab in 14.4% of patients, respectively. Opportunistic infections were rarely reported in our cohort (< 1% of treated patients). However, TNF-antagonist therapy is well known to be associated with an increased risk of severe and opportunistic infections in patients with IBD [25] . An analysis from the Crohn's Therapy, Resource, Evaluation, and Assessment Tool (TREAT) registry found that infliximab exposure was associated with severe infections [hazard ratio (HR) = 1.4, 95% CI: 1.1-1.8] even after adjusting for other factors such as disease activity, steroid use, and narcotic use [26] . In addition to severe infections, IBD patients exposed to TNF-antagonists are also at risk of developing opportunistic infections. A recent meta-analysis of 22 randomized-controlled trials found that opportunistic infections developed in 0.9% of patients receiving TNF-antagonist therapy versus 0.3% of patients under placebo (relative risk = 2.1, 95% CI: 1.1-3.9) [27] . Infusion reactions under infliximab leading to drug discontinuation were observed in 2.5% of treated IBD patients in the SIBDC. These data are in agreement with the literature showing that infusion reactions occur with 3-17% of infliximab infusions [28] . As shown by Cheifetz et al. [29] in a cohort of 165 patients receiving 479 infusions over a 3-year period, the majority of infusion reactions are mild and rarely lead to infliximab discontinuation. We found injection-site reactions leading to drug discontinuation in 0.2% of adalimumab-treated patients and in none of the patients treated with certolizumab pegol. Our findings are in agreement with the literature showing that injection-site reactions can occur in up to 5% of adalimumab-treated patients [27] . In contrast to this finding, patients receiving certolizumab pegol had a lower rate of injection-site reactions than patients receiving placebo (3 vs. 14%) [28] . Psoriasiform and eczematiform lesions may also develop under TNF-antagonist treatment [30] . We found that 3.5, 2.2, and 4.2% of IBD patients treated with infliximab, adalimumab, and certolizumab pegol, respectively, discontinued their drug because of skin reactions. These data are again in agreement with studies showing an incidence of eczematiform and psoriatic lesions to be 9-16% [31] . Of these, up to 34% of patients ultimately discontinue TNF-antagonist therapy [32] .
Cyclosporine and tacrolimus are effective in inducing clinical response and remission in UC patients with severe disease [33] . The main adverse reactions include renal dysfunction, tremor, hirsutism, hypertension, gum hyperplasia, and gastrointestinal intolerance [33] . In our cohort, we found that 13.5% of patients treated with cyclosporine and/or tacrolimus, respectively, had to discontinue treatment because of adverse events. The most frequently cited reasons for drug discontinuation were hypertension and gastrointestinal intolerance.
Aminosalicylates (5-ASA) are considered to be relatively safe and have similar adverse events compared with placebo. Most frequent adverse events are diarrhea (3%), headache (2%), nausea (2%), rash (1%), and thrombocytopenia (< 1%) [6] . In our cohort, a total of 7.9% of patients discontinued their 5-ASA treatment because of adverse events. The most frequent reasons for 5-ASA discontinuation were nausea/diarrhea (0.9% of all 5-ASAtreated patients), gastrointestinal intolerance (0.4%), and nephritis (0.3%).
Systemic glucocorticoids are effective in inducing remission in both CD and UC, whereas they are ineffective in the maintenance of remission in both diseases [34, 35] . However, their use is limited by their frequent side effects [36] . The most frequent side effects occur in the skin, such as thinning of the skin or purpura. Steroids can induce both osteoporosis and osteonecrosis. Furthermore, they increase the susceptibility to various fungal, viral, and bacterial infections. Steroids can cause various psychologic complications such as depression, insomnia, or euphoria. Other potential side effects include myopathy, cushingoid features, redistribution of body fat, hyperlipidemia, hyperglycemia or overt diabetes, and ophthalmologic complications such as cataract or glaucoma. Despite the high prevalence of steroid-related side effects described in the literature, only 5.3 and 4.7% of patients treated with topical and systemic steroids discontinued these drugs because of side effects in our cohort. The most frequent reasons for glucocorticosteroid discontinuation were cushingoid features (0.6% of all steroid-treated IBD patients), gastrointestinal intolerance (0.4% of all steroidtreated IBD patients), osteoporosis/osteopenia (0.2%), psychosis (0.2%), edema (0.2%), and diabetes (0.1% of all steroid-treated IBD patients). We were intrigued that, despite the large variety of possible side effects, the discontinuation rate for steroids in our cohort was even lower than the one for 5-ASA. This finding might be explained by the fact that steroids are typically used for induction of response and remission and not for maintenance treatments, which is in contrast to the use of the other drugs described above.
We identified UC diagnosis (OR = 0.735), presence of EIM (OR = 2.262), IBD-related surgery (OR = 1.419), and the increasing number of concomitantly used IBD drugs (OR = 2.007 for two concomitantly used IBD drugs; OR = 3.225 for at least three concomitantly used IBD drugs) to be associated significantly with the occurrence of IBD drug-related adverse events that necessitated drug cessation. It is noteworthy that the use of at least three concomitantly used IBD drugs showed the strongest association with IBD drug-related adverse events necessitating treatment discontinuation. The SONIC trial showed that a greater proportion of immunomodulator and biologic-naive patients with moderate-to-severe CD who were treated with a combination of azathioprine and infliximab achieved steroid-free remission at 6 months compared with patients treated with infliximab or azathioprine alone (75 vs. 44 vs. 30%) [9] . In this trial, the rates of serious infections were similar between azathioprine alone, infliximab alone, and the combination therapy (4.6, 4.9, and 3.9%) [9] . However, an analysis of CD patients who were treated with steroids, immunomodulators, and/or anti-TNF-α agents found that CD patients receiving at least two of these drugs had higher rates of infections including tuberculosis (HR = 7.4; 95% CI: 2.1-26), candidiasis (HR = 3.8; 95% CI: 2.0-7.6), and herpes zoster (HR = 3.7; 95% CI: 1.8-7.5) compared with control patients and patients receiving only one of these drugs [26] .
Our study does have strengths and some limitations as well. We present data from a large national cohort with a median disease duration of 12 years. We report on the frequency and type of drug-related side effects necessitating treatment discontinuation, which represents a strong outcome. To the best of our knowledge, this is the first large cohort study that convincingly shows the increased risk developing adverse drug events requiring treatment discontinuation when combining different IBD drugs. As a first limitation, the SIBDCS is not population based as 80% of patients are recruited in a hospital setting and only 20% of patients are recruited by gastroenterologists in private practice. Therefore, data cannot be generalized to the entire IBD population. Second, the follow-up questionnaires of the SIBDCS do not capture detailed information on the duration of the different treatments, nor do they assess, for example, blood levels of metabolites of azathioprines and neither drug levels of TNF-antagonists. Third, data capture once a year may also predispose to under-reporting of events.
Conclusion
Over a median disease duration of 12 years, two-thirds of patients experienced IBD drug-related side effects that required treatment discontinuation. Drug-related side effects necessitating treatment discontinuation were most frequently observed for thiopurines, followed by methotrexate, TNFantagonists, cyclosporine, 5-ASA, and steroids. The number of concomitantly used IBD drugs was the strongest predictor for experiencing IBD drug-related side effects necessitating treatment discontinuation. Physicians involved in the care of patients with IBD should maintain a high level of awareness of the potential occurrence of drug-related side effects in the follow-up of their patients, particularly when combining different IBD drugs.
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